Reach and Engagement of Genetic Education, Risk Assessment, and Testing Feasibility (GENET) for PDAC risk

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized feasibility trial compares online education alone versus online education plus a phone-based navigation from PanCAN to promote uptake of genetic testing and MCED testing among individuals at risk for pancreatic cancer. Participants are aged 50 or older (or within 10 years of the earliest PDAC diagnosis in a family) and reside in Massachusetts, with Medicaid, Black, or Latino/a identities. The primary goals are to assess practicality, acceptability, and delivery of the remote education model, with three surveys completed during participation. The study focuses on reducing barriers to cancer genetics and early detection services in historically underserved populations. Lead institution is Brigham and Women’s Hospital, with collaborators PanCAN, Exact Sciences, and Dana-Farber Cancer Institute.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Aged 50 years or older OR 10 years younger than the earliest PDAC diagnosis in a family member
* Current Medicaid enrollment and/or Black and/or Latino/a
* Willingness to travel to Dana-Farber Cancer Institute in Boston, MA, for diagnostic testing if MCED screening test indicates possible malignancy
* Living in the state of Massachusetts
* No prior multi-gene panel genetic testing related to PDAC genetic risk
* Internet access to complete study surveys
* English speaking
* Willing to complete study surveys
* At least one first-degree relative with a PDAC diagnosis by participant report OR Any blood relative with a known pathogenic or likely pathogenic variant in a cancer susceptibility gene related to PDAC by participant report (e.g. ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, STK11, or TP53)

Exclusion Criteria:

* Less than age 50 years or age not within 10 years of the earliest PDAC diagnosis in their family
* Cancer diagnosis in the last 3 years (excluding non-melanoma skin cancers)
* Currently pregnant
* Insurance other than Medicaid or race/ethnicity other than Black or Latino/a
* Prior genetic testing related to PDAC genetic risk
* Genetic counseling in the last 3 years
* Living in a state other than Massachusetts
* Language other than English
* Three members of the same family already enrolled in the study

Where it's running

• Dana-Farber Cancer Institute
  Boston, Massachusetts, United States Recruiting

Study contacts

• Principal investigator: Nicolette J Rodriguez, MD, MPH — Brigham and Women's Hospital
• Study coordinator: Tia Kauffman, MPH
• Email: tial_kauffman@dfci.harvard.edu
• Phone: 857-215-1892

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• KRAS Inhibitor ETX-929 in advanced solid tumors

  This trial tests ETX-929, alone or with cetuximab, in people whose cancers have KRAS mutations and have progressed after prior therapy.

  Recruiting Phase 1/2 Ensem Therapeutics · Fairfax, Virginia · NCT07912593

• Modified FOLFIRINOX with Pentamidine in Advanced Pancreatic Cancer

  This study tests whether adding pentamidine to a modified FOLFIRINOX regimen helps people with advanced or metastatic pancreatic cancer.

  Recruiting Phase 1 University of Oklahoma · Oklahoma City, Oklahoma · NCT07829185

• Targeted alpha-radiation therapy for NTSR1-positive tumors using SKL35501/SKL35502

  This early-phase trial tests whether a two-part approach—an imaging agent to find NTSR1-expressing tumors and a targeted alpha-ray therapy—can be safely used in adults with certain advanced solid tumors.

  Recruiting Phase 1 SK Life Science, Inc. · Glen Burnie, Maryland and 4 other locations · NCT07812805

• Zoldonrasib plus Daraxonrasib vs Gemcitabine and Nab-Paclitaxel as first-line treatment for metastatic KRAS G12D pancreatic cancer

  This study tests whether two investigational RAS inhibitors together can improve outcomes compared with standard chemotherapy in adults with newly diagnosed metastatic pancreatic cancer carrying the KRAS G12D mutation.

  Recruiting at 6 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 5 other locations · NCT07805954

• Imaging study of 203Pb-RMX-VH-PIB in GBM and PDAC patients

  This early-stage study tests a new imaging drug to see how it travels in the body and how much radiation different organs receive in adults with GBM or PDAC.

  Recruiting Phase 1 Radiomedix, Inc. · Houston, Texas · NCT07733674

• Breath test to help detect gastrointestinal cancers early

  A breath test that looks for signals in exhaled air to see if someone with gut cancer symptoms might have oesophageal, stomach, pancreatic, liver, or colorectal cancer and need urgent testing.

  Recruiting Imperial College London · Maidstone, Kent and 5 other locations · NCT07714538

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.